Skip to main content
Medical information Clinical review pending

Genetic Testing

IL1RAPL1 Gene Mental Retardation X-Linked Type 21 Genetic Test

This genetic test identifies mutations in the IL1RAPL1 gene associated with X-linked mental retardation type 21. It uses advanced Next Generation Sequencing (NGS) technology to help diagnose developmental delays and intellectual disabilities, particularly in families with a history of neurological disorders.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
A blood sample is required for this test. Please confirm specific volume and collection tube requirements with the laboratory before sample collection.
Results
Confirm with the laboratory before booking.
Preparation
No special preparation is typically required for a blood draw. However, please confirm any specific instructions with the laboratory or your physician.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the IL1RAPL1 Gene Mental Retardation X-Linked Type 21 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Developmental delays
  • ✓Intellectual disabilities
  • ✓Suspected X-linked mental retardation
  • ✓Family history of neurological disorders
  • ✓Genetic counseling for families with affected members
  • ✓Diagnosis confirmation when clinical features are suggestive
02

In plain language

What this test helps you understand

This test helps confirm or rule out a diagnosis of X-linked mental retardation type 21 caused by mutations in the IL1RAPL1 gene. It can provide a definitive genetic diagnosis for individuals presenting with developmental delays or intellectual disabilities, especially when a family history suggests a genetic component. The results can guide clinical management, prognosis, and genetic counseling for affected individuals and their families.
The IL1RAPL1 Gene Mental Retardation X-Linked Type 21 NGS Genetic DNA Test is a diagnostic tool used to detect specific genetic mutations in the IL1RAPL1 gene. These mutations are linked to a rare condition known as X-linked mental retardation type 21, which can cause developmental delays and intellectual disabilities. This test is particularly relevant for individuals and families where there is a suspected genetic cause for these symptoms.

This test utilizes Next Generation Sequencing (NGS) technology, a highly accurate method for analyzing DNA. It examines the IL1RAPL1 gene for variations that may be responsible for the condition. Identifying these mutations can provide a definitive diagnosis, which is crucial for understanding the cause of the symptoms and guiding appropriate medical care and support.

Understanding the genetic basis of a condition can also be important for family planning and genetic counseling, helping families understand the risk of passing the condition to future generations.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is typically required for a blood draw. However, please confirm any specific instructions with the laboratory or your physician.
SampleA blood sample is required for this test. Please confirm specific volume and collection tube requirements with the laboratory before sample collection.
MethodologyNext Generation Sequencing (NGS) is used to analyze the IL1RAPL1 gene for mutations.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the IL1RAPL1 gene. It will not detect mutations in other genes that can cause similar symptoms. A negative result does not completely rule out a genetic cause for the symptoms, as other genetic factors may be involved. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

This is a rare genetic condition primarily affecting males, characterized by developmental delays and intellectual disabilities, caused by mutations in the IL1RAPL1 gene.
Individuals experiencing developmental delays or intellectual disabilities, especially males, and families with a history of similar conditions should discuss this test with their doctor.
A blood sample is required for the genetic analysis.
Next Generation Sequencing (NGS) is a highly accurate method for detecting mutations in the IL1RAPL1 gene. However, limitations exist, and results should be interpreted by a healthcare professional.
Results will be provided, and interpretation, often involving a genetic counselor, is recommended to understand the findings and their implications.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp